Skip to main content
BCAX
NASDAQ Life Sciences

Bicara Therapeutics启动FORTIFI-HN01 3期试验，目标年底完成招募

feedReported by Dow Jones Newswires
Sentiment info
Positive
Importance info
8
Price
$19.39
Mkt Cap
$1.164B
52W Low
$7.8
52W High
$20.25
Market data snapshot near publication time

summarizeSummary

Bicara Therapeutics宣布启动其关键的3期FORTIFI-HN01研究。这一重要的药物开发里程碑表明生物技术公司朝着潜在的市场批准迈进。该公司预计将在年底之前在试验中实现大量招募，为投资者提供明确的时间表。这一发展是一个积极的催化剂，降低了药物的风险，并可能增加其成功的概率，这对于像Bicara这样的公司规模至关重要。投资者现在将关注招募进度更新和来自该关键研究的未来数据结果。

在该公告发布时，BCAX的交易价格为$19.39，交易所为NASDAQ，所属行业为Life Sciences，市值约为$11.6亿。 52周交易区间为$7.80至$20.25。 这则新闻被评估为积极市场情绪，重要性评分为8/10。 来源：Dow Jones Newswires。

show_chartPrice Chart

Share this article

Copied!

feed BCAX - Latest Insights

BCAX
Mar 30, 2026, 5:30 PM EDT
Filing Type: 10-K
Importance Score:
8
Bicara Therapeutics Reports Increased Losses Amid Pivotal Phase 3 Trial Advancement and Strong Cash Runway
Sentiment: Positive
View Wiseek Article
BCAX
Mar 30, 2026, 7:59 AM EDT
Source: Reuters
Importance Score:
7
Bicara Therapeutics Reports Q4 Net Loss of $37.4M, Confirms Phase 3 Trial Initiation
Sentiment: Neutral
View Wiseek Article
BCAX
Mar 30, 2026, 7:47 AM EDT
Filing Type: 8-K
Importance Score:
8
Bicara Therapeutics Initiates Pivotal Phase 3 Trial and Secures $161.8M in Oversubscribed Offering, Extending Cash Runway to 2029
Sentiment: Positive
View Wiseek Article
BCAX
Mar 30, 2026, 7:31 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Bicara Therapeutics Kicks Off Phase 3 Trial for FORTIFI-HN01, Targeting Year-End Enrollment
Sentiment: Positive
View Wiseek Article
BCAX
Mar 02, 2026, 4:25 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
RA Capital Management Invests $40M in Bicara Therapeutics Public Offering, Boosting Stake to 11.5%
Sentiment: Positive
View Wiseek Article
BCAX
Mar 02, 2026, 4:22 PM EST
Filing Type: 4
Importance Score:
8
RA Capital Management Details $40M Purchase of Bicara Therapeutics Stock and Warrants
Sentiment: Positive
View Wiseek Article
BCAX
Feb 26, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
7
Bicara Therapeutics Closes $161.8M Public Offering, Bolstering Cash for Drug Development
Sentiment: Neutral
View Wiseek Article
BCAX
Feb 25, 2026, 9:50 PM EST
Filing Type: 424B5
Importance Score:
8
Bicara Therapeutics Finalizes $150M Public Offering of Common Stock and Warrants at Discount
Sentiment: Negative
View Wiseek Article
BCAX
Feb 24, 2026, 9:47 PM EST
Filing Type: FWP
Importance Score:
8
Bicara Therapeutics Amends Public Offering to Include Pre-Funded Warrants for $150M Capital Raise
Sentiment: Neutral
View Wiseek Article
BCAX
Feb 24, 2026, 4:27 PM EST
Filing Type: 424B5
Importance Score:
7
Bicara Therapeutics Announces $150M Public Offering to Fund Pipeline Advancement
Sentiment: Neutral
View Wiseek Article